tbuckley/cabot-search huggingface dataset:
AB0687 Factors associated with common warts in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE):
Authors: M.U. Martinez Martinez, L. Baranda-Cándido, C. Abud-Mendoza
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Previous studies demonstrated an increased prevalence of human papillomavirus (HPV) related CW in patients with SLE.<sup>1</sup> Problems associated with previous published series include the fact that sample sizes were small for both SLE patients and controls; moreover, the reported prevalence was not adjusted for immunosuppressive agents. <h3>Objectives</h3> To evaluate factors associated with skin CW in patients with RA and SLE, and to determine whether SLE itself is an independent risk factor for CW. <h3>Methods</h3> We included 670 patients in consecutive selection in this cross sectional study (550 with RA and 120 with SLE). All patients were evaluated by a dermatologist and two rheumatologists; patients with CW were selected as cases (63) and the other 607 patients were selected as controls. A structured questionnaire was administered to the subjects to ascertain the possible risk factors associated with CW. Parametric statistics were performed; categorical measurements were compared using X<sup>2</sup> or exact Fisher's test. Logistic regression was used to adjust for potential confounding variables. <h3>Results</h3> The prevalence of CW was increased 2.8-fold in SLE patients (20%) compared with RA (7.1%). When comparing cases (patients with common warts=63) with controls (607), univariate analysis (Table 1) showed statistically significant differences for age, having SLE, and treatment with mycophenolate mofetil (MMF). When all of the potential risk factors identified using univariate analysis (age, having SLE, and MMF) were put into a multivariate model, independent risk factors for CW were having SLE (odds ratio: 2.16, 95% confidence interval: 1.04-4.48) and MMF therapy (odds ratio: 2.91, 95% confidence interval: 1.18-7.14). <h3>Conclusions</h3> CW were more common in patients with SLE. MMF is an independent risk factor to the development of CW. The relationship of MMF and HPV gynecological infection should be studied because its association with cancer. Our findings may have an implication for the selection of SLE therapy. <h3>References</h3> Korkmaz C, Urer SM. Cutaneous warts in patients with lupus erythematosus. Rheumatol Int 2004;24:137-40. <h3>Disclosure of Interest</h3> None Declared
Endoscopic ultrasound in cystic pancreatic lesions: operator training needs to be improved, EUS-guided sampling should be standardized, and decision-making should be multidisciplinary and evidence-based
Authors: L. Palazzo, D. O’Toole
Journal: Endoscopy (2011)

Management strategies for cystic pancreatic lesions (CPLs) currently present a real challenge as the number of incidentally discovered lesions appears be increasing in parallel with improvements in and greater use of modern imaging methods [1]. The accompanying advances of expertise in pancreatic medicine and surgery have identified the basic criteria for categorizing CPLs into two distinct groups. Group 1 are malignant or premalignant CPLs, and are mucinous (mucinous cystadenomas or intraductal papillary mucinous neoplasms [IPMNs]), or nonmucinous (essentially comprising cystic neuroendocrine tumors and rare papillary cystic neoplasms). Group 2 are benign CPLs, and include pseudocysts, serous cystadenomas (the macrocystic type can pose diagnostic challenges [2]), cystic lymphangiomas, mesenteric/peritoneal cysts, lymphoepithelial cysts, and rare benign pancreatic cysts (isolated or associated with polycystic pancreatic disorders).
S84 Childhood incident asthma and physical activity: a systematic literature review and meta-analysis with heterogeneity assessments
Authors: L. Lochte, R. Granell, J. A. C. Sterne, A. J. Henderson
Journal: Thorax (2010)

<h3>Introduction and Objectives</h3> Physical activity (PA) has been found to be associated with prevalent childhood asthma but evidence from cross-sectional studies is inconclusive; demonstrating both positive and negative associations of PA with asthma. The aim of this study was to systematically review and meta-analyse the literature on PA and incident or “new-onset” childhood asthma. <h3>Methods</h3> Medline, Embase, and the Cochrane Library were searched for articles on the associations between PA and asthma, restricted to age group 0–18 years and publications 1995–2010. PA was searched by 9physical fitness, exercise, physical exertion9 and asthma additionally qualified by FEV<sub>1</sub>, BHR, EIA, EIB, exercise test and wheeze. Summary ORs and 95% CIs were estimated by random and fixed effect models. The robustness was explored by subgroup (ethnicity) and sensitivity (cut-point alteration) analysis. <h3>Results</h3> Twenty-seven articles were included in the systematic review which comprised nine longitudinal, 15 cross-sectional, one case-control, and two review studies. Five studies featured longitudinal observations and were included in the meta-analysis (total participants n=12 889; total new-onset asthma n=912). Meta-analysis of these studies showed the following associations of high PA with new-onset asthma: Random effect model: OR (95% CI) 0.854 (0.713; 1.023) (Abstract S84 Figure 1) and fixed effect model: 0.909 (0.855; 0.967). I-squared=62.7% (both models). <h3>Conclusion</h3> The results of this review did support some inverse association between high levels of PA and asthma development in children. However, a limited number of eligible studies were identified and considerable heterogeneity was present.
MEDICATION COVERAGE GAPS GREATER IN BLACKS THAN IN WHITES MAY EXPLAIN DISPARITY IN BP CONTROL FOR BLACKS
Authors: Ross D. Fletcher, Richard Amdur, Raya Kheirbek, Vasilios Papademetriou, Ali Ahmed, Farrokh Alemi, David Maron, Charles Faselis, Ronald Jones
Journal: Journal of the American College of Cardiology (2016)
The mTORC Pathway in the Antiphospholipid Syndrome
Authors: John W. Eikelboom, Jeffrey I. Weitz
Journal: New England Journal of Medicine (2014)

The antiphospholipid syndrome is an acquired autoimmune disorder characterized by thrombotic events, miscarriages, and elevated levels of antiphospholipid antibodies.1 The syndrome is described as secondary if associated with autoimmune diseases, such as lupus erythematosus or rheumatoid arthritis, and as primary if not. The most common thrombotic manifestation of the antiphospholipid syndrome is venous thrombosis, which is usually manifested as deep-vein thrombosis, with or without pulmonary embolism, but arterial thrombosis can also occur, particularly in the context of transient cerebral ischemia or stroke. In rare instances, extensive microvascular thrombosis leads to multiorgan failure involving the brain, lungs, and kidneys, a condition . . .
Abstract 1340: High densities of tumor-infiltrating FOXP3+ regulatory T cells in primary tumor or lymph node metastasis are associated with favorable outcome in gastric cancer
Authors: Hee Eun Lee, Seoung Wan Chae, You Jeong Lee, Min A Kim, Hye Seung Lee, Byung Lan Lee, Woo Ho Kim
Journal: Cancer Research (2010)

Abstract Background: It has been reported that the frequency of FOXP3+ regulatory T cells (Tregs) among tumor-infiltrating lymphocytes is increased in cancer-bearing patients. We designed the study to determine the prognostic significance of FOXP3+ Tregs in gastric cancer. Methods: Tissue microarray and immunohistochemistry were used to assess the densities of FOXP3+ T regs in primary tumor tissue (n=216) and unmatched metastatic tumor tissue of regional lymph nodes (n=149) from gastric cancer patients. Numbers of FOXP3+ Tregs were counted using an image analysis program. FOXP3+ Treg densities were evaluated for correlation with clinicopathologic characteristics and overall survival. Results: With respect to primary tumor, low density of FOXP3+ Tregs was associated with advanced T stage (p = 0.028), but not with any other clinicopathologic features. Kaplan-Meier survival analysis revealed that the high density group of FOXP3+ Tregs had longer survival time than the low density group (p = 0.001, log-rank test). In multivariate analysis, FOXP3+ Treg density remained an independent prognostic factor with hazard ratio (95% CI) of 0.651 (0.435-0.975). In addition, it was found that FOXP3+ Treg density in metastatic tumor of lymph nodes was an independent prognostic indicator, i.e., high density of FOXP3+ Tregs was significantly associated with improved survival (hazard ratio (95% CI) = 0.519 (0.318-0.848)). Conclusions: FOXP3+ Treg densities in not only primary tumor, but also metastatic loci of regional lymph nodes were significantly associated with patient survival in gastric cancer. As our finding that high density of FOXP3+ Tregs was related to favorable prognosis contrasts with several previous studies, further investigation will be needed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1340.
What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance
Authors: Marta Palomo, Enrique Mir, Montse Rovira, Ginés Escolar, Enric Carreras, Maribel Diaz-Ricart
Journal: Blood (2016)

Defibrotide (DF) has received European Medicines Agency authorization to treat sinusoidal obstruction syndrome, an early complication after hematopoietic cell transplantation. DF has a recognized role as an endothelial protective agent, although its precise mechanism of action remains to be elucidated. The aim of the present study was to investigate the interaction of DF with endothelial cells (ECs). A human hepatic EC line was exposed to different DF concentrations, previously labeled. Using inhibitory assays and flow cytometry techniques along with confocal microscopy, we explored: DF-EC interaction, endocytic pathways, and internalization kinetics. Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effects on endothelium were dependent of its internalization. Confocal microscopy showed interaction of DF with EC membranes followed by internalization, though DF did not reach the cell nucleus even after 24 hours. Flow cytometry revealed concentration, temperature, and time dependent uptake of DF in 2 EC models but not in other cell types. Moreover, inhibitory assays indicated that entrance of DF into ECs occurs primarily through macropinocytosis. Our experimental approach did not show any evidence of the involvement of adenosine receptors in DF-EC interaction. The antiinflammatory and antioxidant properties of DF seem to be caused by the interaction of the drug with the cell membrane. Our findings contribute to a better understanding of the precise mechanisms of action of DF as a therapeutic and potential preventive agent on the endothelial damage underlying different pathologic situations.
Recent Advances in Radiation Oncology
Authors: Allen S. Lichter, Theodore S. Lawrence
Journal: New England Journal of Medicine (1995)

Nearly 500,000 patients in the United States were treated with radiation in 1990,1 making radiotherapy one of the most widely used treatments for cancer. In this article we discuss advances that have occurred since the subject of radiation oncology was last reviewed in the Journal, over a decade ago.2 We begin by summarizing the biologic responses of cells to radiation, particularly as they relate to the development of new therapies. We then discuss developments in the physics of radiation therapy, especially the influence of high-speed computers and graphics displays on the accuracy of radiation treatment. Finally, we discuss clinical advances . . .
Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients.
Authors: R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I. Simon, K. Janssen, H. Friess
Journal: Journal of Clinical Oncology (2010)

3513 Background: Adjuvant therapy is not routinely recommended for stage II CC patients but may be considered for high-risk patients. In this study we aim to independently validate a genomic profile that was developed to identify high risk patients and can assist in treatment decisions. Methods: An 18-gene profile had been developed using gene expression data from whole genome Agilent 44K oligonucleotide arrays and was validated in samples from an independent cohort of 178 stage II/III CC patients and in in silico datasets (Salazar et al. 2010 submitted). The profile was translated into a robust diagnostic test (ColoPrint) using the Agilent 8-pack arrays. For this study, 232 patients who underwent curative resection (R0) for colon cancer stages II or III at the Klinikum rechts der Isar from 1987 to 2003 were selected. Fresh frozen tissues, clinical parameters and follow-up data for all patients were available. The samples were hybridized to 8- pack arrays and the ColoPrint index was determined for all samples blinded from the clinical data. Results: Patients in this study had a median age of 64 years and median follow-up of 97 months. The median number of resected lymph nodes was 21, giving an indirect measure of the quality of surgery. In the 137 stage II patients, ColoPrint identified most patients (74%) as low risk. The 5-year distant-metastasis-free survival was 95% for low risk patients and 79.9% for high risk patients. In the univariate analysis, ColoPrint was the only significant parameter to predict the development of distant metastasis with a HR of 4.3 (95% CI 1.36-13.56, p = 0.007). Using clinical parameters from the ASCO recommendation (T4, perforation, less than 12 LN assessed and/ or high grade) for the identification of high-risk patients was not significant (HR 2.1; 95% CI 0.64-7.04, p = 0.2) and did not add power to the ColoPrint classification. Risk assessment by ColoPrint in mostly treated stage III patients (n = 97) classified 75% as low risk and 25% as high risk and was not significantly correlated. Conclusions: ColoPrint is able to predict the development of distant metastasis of stage II colon cancer patients and facilitates the identification of patients who may benefit from adjuvant chemotherapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Agendia Agendia
Effectiveness in Health Care
Authors: William L. Roper, William Winkenwerder, Glenn M. Hackbarth, Henry Krakauer
Journal: New England Journal of Medicine (1988)

ALTHOUGH modern medicine provides great benefits to large numbers of people, medical professionals and clinical researchers have expressed concern about the effectiveness and appropriateness of many current and emerging medical practices. For example, the evidence substantiating the effectiveness of many such practices is frequently questionable and in many instances entirely lacking.1 Research on medical interventions is often poorly designed and methodologically flawed.2 , 3 Many physicians lack the skills to interpret and critically evaluate medical literature,4 and they approach the same clinical problem with different theoretical assumptions, contributing to wide variations in practice patterns.5 , 6 Furthermore, physicians have difficulty incorporating information about probabilities . . .
SAT0360 HFE C282Y/H63D Compound Heterozygotes are at Lower Risk of Hemochromatosis-Related Arthropathy
Authors: T. Funck-Brentano, F. Bailly, E. Vicaut, S. Ottaviani, T. Bardin, P. Richette
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Arthropathy that mimics osteoarthritis (OA) and osteoporosis (OP) are considered classic complications of hereditary hemochromatosis (HH). There are limited data comparing OA and OP among HH patients with different HFE genotypes. <h3>Objectives</h3> We investigated whether C282Y homozygosity was associated with an increased prevalence of OA and OP and related factors as compared to duplex heterozygosity (C282Y/H63D) in patients with HH. <h3>Methods</h3> A questionnaire was completed by 306 patients with HH. Demographic characteristics, the presence of OA or OP were compared according to the genotype (C282Y/C282Y vs. C282Y/H63D) using logistic regression models with adjustment for sex, age and body mass index (BMI). <h3>Results</h3> A total of 284 HH patients were included in this study: 229 (80.6%) were C282Y homozygous whereas 55 (19.4%) were C282Y/H63D heterozygous. Mean age was 59.9 +/- 10.9 year in both groups. Patients with homozygosity had higher ferritin levels at diagnosis (1730 +/- 1736 ng/ml vs. 972 +/- 190 ng/ml, p&lt;0.001) and had a lower BMI (24.5 +/- 3.8 kg/m2 vs. 26.5 +/- 3.9 kg/m2, p=0.004). The overall prevalence of OA was higher in homozygous than in heterozygous patients: 44.01% vs. 6.69%, p=0.009 [aOR = 2.3 (CI95% 1.2 to 4.3), p= 0.01]). Furthermore, homozygosity was associated with an increased risk of knee and hip replacement: 11.7% vs. 0.71% p=0.047. This association was no longer significant in multivariate analyze (OR=3.5 CI95% 0.8 to 15.6, p=0.099). We then restricted the analysis to patients with ferritin levels above 1000 ng/ml, and found that the association between OA and the homozygous genotype was even higher (OR = 4.14 CI95% 1.2 to 13.8, p=0.02). Finally, we found a trend for a higher prevalence of OP or any bone fracture in the homozygous group: 19.4% vs. 3.2% p=0.22 and 23.8% vs. 4.6%, p=0.43, respectively. <h3>Conclusions</h3> This study strongly suggests that duplex heterozygosity confers a lower risk of HH-related musculoskeletal complications. <h3>Disclosure of Interest</h3> None Declared
Abstract 511: Characterization of humoral response profiles of ovarian cancer patients as diagnostic biomarkers
Authors: Carolyn D. Roberson, Cicek Gercel-Taylor, Douglas D. Taylor
Journal: Cancer Research (2012)

Abstract Ovarian cancer is the 5th leading cause of cancer death among women and is the leading cause of death among gynecologic malignancies as a result of limitations in early diagnosis. It is associated with the induction of humoral immunity, characterized by the generation of IgG against a wide range of tumor-associated antigens. Although the role of circulating tumor-reactive IgG is unclear, it has been demonstrated to correlate with poor prognosis and survival. The use of tumor-reactive IgG as a potential diagnostic and/or prognostic tool has been limited since most studies have identified components with shared expression in non-neoplastic tissue and failed to define targets exhibiting ubiquitous expression in ovarian cancers. A number of these limitations result from the use of recombinant proteins (translated in non-mammalian cells) as targets to define immunoreactivity. The power in utilizing the autologous humoral response is its ability to define alterations which might lead to the altered appearance or aberrant association of antigen with other cellular components, thereby resulting in the induction of humoral responses. We therefore hypothesize that the ovarian patient humoral response to specific tumor antigens can serve as diagnostic biomarkers of ovarian cancer. To investigate patients’ humoral response to “natural” tumor antigens, ovarian tumor cell lysates and tumor-derived exosomes were separated into antigenic proteins by first dimension isoelectric focusing via an immobilized pH gradient and/or rotofor fractionation. Reactive proteins were further separated by second dimension SDS-PAGE, followed by western immunoblotting using autologous or heterologous patient sera. Circulating tumor-reactive IgG was found to recognize shared (MW 37-75 kD, pI 3.0-5.5) and distinct (MWexo ∼50 kD, pI 9.0-10.5; MWlys∼15 kD, pI 4.3-6.5) ovarian tumor cell proteins. Recognition of these antigenic proteins was not observed using antibodies derived from normal control patients. Collectively, our data supports that the circulating IgG produced in the ovarian cancer humoral response recognizes specific tumor antigens (many of which are shared among cancer patients) and will thus have utility in diagnosing these patients. Further identification of these antigenic proteins by mass spectrometry will produce specific diagnostic targets and may provide insights on common driver mechanisms in ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 511. doi:1538-7445.AM2012-511
N-(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells
Authors: A. Mariotti, E. Marcora, G. Bunone, A. Costa, U. Veronesi, M. A. Pierotti, G. D. Valle
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article N -(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells Get access Agnese Mariotti, Agnese Mariotti *Affiliations of authors: Dipartimento di Genetica e Microbiologia, A. Buzzati Traverse, Universitàdi PaviaPavia, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Edoardo Marcora, Edoardo Marcora *Affiliations of authors: Dipartimento di Genetica e Microbiologia, A. Buzzati Traverse, Universitàdi PaviaPavia, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Giuseppe Bunone, Giuseppe Bunone *Affiliations of authors: Dipartimento di Genetica e Microbiologia, A. Buzzati Traverse, Universitàdi PaviaPavia, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Alberto Costa, Alberto Costa European Institute of OncologyMilano, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Umberto Veronesi, Umberto Veronesi Istituto Nazionale TumoriMilano Search for other works by this author on: Oxford Academic PubMed Google Scholar Marco A. Pierotti, Marco A. Pierotti Istituto Nazionale TumoriMilano Search for other works by this author on: Oxford Academic PubMed Google Scholar Giuliano Della Valle Giuliano Della Valle *Affiliations of authors: Dipartimento di Genetica e Microbiologia, A. Buzzati Traverse, Universitàdi PaviaPavia, Italy Correspondence to : Giuliano Della Valle, Dipartimento di Genetica e Microbiologia, A. Buzzati Traverso, Università di Pavia, Via Abbiategrasso 207, 27100 Pavia, Italy. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 16, 17 August 1994, Pages 1245–1247, https://doi.org/10.1093/jnci/86.16.1245 Published: 17 August 1994 Article history Received: 04 January 1994 Revision received: 21 April 1994 Accepted: 05 May 1994 Published: 17 August 1994